282 related articles for article (PubMed ID: 32643529)
1. Natural-like products as potential SARS-CoV-2 M
Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Hegazy MF
J Biomol Struct Dyn; 2021 Sep; 39(15):5722-5734. PubMed ID: 32643529
[TBL] [Abstract][Full Text] [Related]
2.
Ibrahim MAA; Abdelrahman AHM; Hegazy MF
J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
[TBL] [Abstract][Full Text] [Related]
3. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
4. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.
Ibrahim MAA; Mohamed EAR; Abdelrahman AHM; Allemailem KS; Moustafa MF; Shawky AM; Mahzari A; Hakami AR; Abdeljawaad KAA; Atia MAM
J Mol Graph Model; 2021 Jun; 105():107904. PubMed ID: 33798836
[TBL] [Abstract][Full Text] [Related]
5. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
[TBL] [Abstract][Full Text] [Related]
6.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
7. Blue Biotechnology: Computational Screening of
Ibrahim MAA; Abdelrahman AHM; Atia MAM; Mohamed TA; Moustafa MF; Hakami AR; Khalifa SAM; Alhumaydhi FA; Alrumaihi F; Abidi SH; Allemailem KS; Efferth T; Soliman ME; Paré PW; El-Seedi HR; Hegazy MF
Mar Drugs; 2021 Jul; 19(7):. PubMed ID: 34356816
[TBL] [Abstract][Full Text] [Related]
8. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (M
Ibrahim MAA; Abdelrahman AHM; Mohamed TA; Atia MAM; Al-Hammady MAM; Abdeljawaad KAA; Elkady EM; Moustafa MF; Alrumaihi F; Allemailem KS; El-Seedi HR; Paré PW; Efferth T; Hegazy MF
Molecules; 2021 Apr; 26(7):. PubMed ID: 33916461
[TBL] [Abstract][Full Text] [Related]
9. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
10. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
[TBL] [Abstract][Full Text] [Related]
11. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
12. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
13. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 M
Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M
Elseginy SA
J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases.
Kumar BK; Faheem ; Sekhar KVGC; Ojha R; Prajapati VK; Pai A; Murugesan S
J Biomol Struct Dyn; 2022 Feb; 40(3):1363-1386. PubMed ID: 32981461
[TBL] [Abstract][Full Text] [Related]
17. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
Majumder R; Mandal M
J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
[TBL] [Abstract][Full Text] [Related]
18. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
[TBL] [Abstract][Full Text] [Related]
19. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
20. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.
Razzaghi-Asl N; Ebadi A; Shahabipour S; Gholamin D
J Biomol Struct Dyn; 2021 Oct; 39(17):6633-6648. PubMed ID: 32705953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
